FY2027 Earnings Estimate for Erasca Issued By HC Wainwright

Erasca, Inc. (NASDAQ:ERAS) – Equities researchers at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Erasca in a research note issued to investors on Monday, January 26th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.50) per share for the year, down from their previous forecast of ($0.40). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Erasca’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca’s FY2028 earnings at ($0.55) EPS, FY2029 earnings at ($0.55) EPS and FY2030 earnings at ($0.37) EPS.

Erasca (NASDAQ:ERAS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11).

A number of other research firms have also recently weighed in on ERAS. Mizuho started coverage on shares of Erasca in a research report on Tuesday. They set an “outperform” rating and a $16.00 price objective on the stock. Morgan Stanley set a $10.00 price target on shares of Erasca in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research report on Thursday, January 22nd. Stifel Nicolaus set a $10.00 price objective on shares of Erasca in a research note on Monday, January 12th. Finally, Guggenheim restated a “buy” rating and set a $12.00 target price on shares of Erasca in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.22.

Erasca Stock Performance

NASDAQ:ERAS opened at $10.13 on Wednesday. The firm has a market capitalization of $3.14 billion, a PE ratio of -22.51 and a beta of 1.15. The stock’s fifty day moving average is $5.05 and its 200 day moving average is $3.02. Erasca has a fifty-two week low of $1.01 and a fifty-two week high of $10.71.

Institutional Trading of Erasca

Institutional investors and hedge funds have recently modified their holdings of the stock. Vivo Capital LLC boosted its holdings in shares of Erasca by 37.2% in the third quarter. Vivo Capital LLC now owns 9,273,428 shares of the company’s stock valued at $20,216,000 after purchasing an additional 2,516,672 shares during the period. Paradigm Biocapital Advisors LP lifted its holdings in shares of Erasca by 13.9% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 13,560,017 shares of the company’s stock worth $29,561,000 after buying an additional 1,652,835 shares during the period. VR Adviser LLC lifted its holdings in shares of Erasca by 10.1% in the 2nd quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after buying an additional 1,640,867 shares during the period. Affinity Asset Advisors LLC grew its position in shares of Erasca by 22.3% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,085,787 shares of the company’s stock worth $5,189,000 after buying an additional 744,268 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Erasca by 594.8% during the first quarter. AQR Capital Management LLC now owns 396,202 shares of the company’s stock valued at $543,000 after buying an additional 339,177 shares during the period. Institutional investors own 67.78% of the company’s stock.

Insiders Place Their Bets

In related news, General Counsel Ebun Garner sold 120,000 shares of Erasca stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $5.59, for a total transaction of $670,800.00. Following the completion of the sale, the general counsel owned 25,076 shares in the company, valued at $140,174.84. This trade represents a 82.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 14.40% of the stock is owned by insiders.

Trending Headlines about Erasca

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: Mizuho initiated coverage with an “outperform” rating and a $16.00 price target, signaling sizable upside vs. the recent price and providing fresh buy-side support. Mizuho Outperform Initiation
• Neutral Sentiment: HC Wainwright reiterated a “Buy” rating and a $15 price target even as it updated its models — the maintained rating supports investor interest but the firm lowered forward EPS estimates. HC Wainwright Coverage
• Negative Sentiment: HC Wainwright cut FY2027–FY2030 EPS forecasts materially (examples: FY2030 to ($0.37) from ($0.02) previously; FY2029 and FY2028 also reduced). Lower earnings outlooks increase uncertainty around valuation and may pressure the stock. HC Wainwright Estimate Cuts
• Negative Sentiment: Short interest surged earlier in January to ~26.6M shares (about 11% of shares outstanding) with a short-interest ratio near 2.2 days — higher short activity can amplify downward price moves and volatility. Note: a later data entry showing zero short interest appears to be an error/contradiction in the reporting.

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.